Mark Froimson
Director · Pacira BioSciences, Inc.
- 2026
- Jun 13, 2026
- 2
Other insiders active in the same stocks
Insiders who reported open-market trades in the last 12 months at the companies Mark Froimson files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
- Shawn Cross - $895K in PCRX purchases and sales in the last 12 months
- Kristen Williams - $498K in PCRX purchases and sales in the last 12 months
- Lauren Riker - $445K in PCRX purchases and sales in the last 12 months
- Jonathan Slonin - $240K in PCRX purchases and sales in the last 12 months
More insiders (A-Z)
Browse nearby insider profiles in alphabetical order.
Frequently asked questions
Who is Mark Froimson?
Mark Froimson is a corporate insider, tracked as Director of Pacira BioSciences, Inc. (PCRX). InsiderAlpha holds 2 primary Form 4 filings for them, the earliest from 2026, updated as new SEC EDGAR filings are processed.
When did Mark Froimson last file a Form 4?
The most recent primary Form 4 on record is dated 13 June 2026, one of 2 filings going back to 2026.
Has Mark Froimson been buying or selling stock?
Recorded transactions: 0 open-market purchases and 1 open-market sale ($11K) across all tracked filings.
